A Phase 2 interventional study of Xyrem (sodium oxybate) oral solution and Xyrem (sodium oxybate) oral solution in Fibromyalgia, sponsored by Jazz Pharmaceuticals. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-24.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
The purpose of this study is to determine whether Xyrem (sodium oxybate) is effective when used alone to treat the pain and sleep disturbances of fibromyalgia.
Fibromyalgia affects millions of Americans, yet there are no FDA approved drugs to treat this debilitating condition. Besides causing pain, it also disrupts normal sleep patterns in many of its victims. Pain and lack of sleep reinforce each other, making patients progressively more miserable. Xyrem is a potent hypnotic that induces and consolidates sleep. In a few small studies Xyrem has been reported to offer relief to some fibromyalgia patients. This trial is designed to test this hypothesis. Patients who enroll in this study will stop taking any prescription medications for fibromyalgia (over-the-counter pain relievers will be permitted). They will then take either Xyrem alone or placebo alone. Patients will be followed for eight weeks to evaluate any relief of the pain or functional impairment of fibromyalgia from their study treatment. Sleep characteristics will also be assessed subjectively and by polysomnographic recordings at baseline and twice during the treatment phase.
1,336 studies on the registry are indexed under Fibromyalgia; 266 are open to participants now.
This study's enrollment of 195 is above the median of 60 across 1,035 interventional studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →Jazz Pharmaceuticals is the lead sponsor of 167 studies on the registry; 20 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Have any of the following medical conditions:
Have taken any of these therapies:
Unwilling to stop these therapies during course of trial:
Have any of the following clinical laboratory results:
Have any of the following socio-economic factors:
Sodium oxybate 6.0 g per day.
Drug: Xyrem (sodium oxybate) oral solution
Placebo (one of two doses matching active treatment by volume).
Drug: Placebo
Sodium oxybate 4.5 g per day.
Drug: Xyrem (sodium oxybate) oral solution
Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
Placebo one of two doses matching active treatment by volume for 8 weeks.
The Primary Outcome Measure Was a Composite of Changes From Baseline in Three Co-primary Self Report Measures: Pain Visual Analog Scale (PVAS, Electronic Diaries), Fibromyalgia Impact Questionnaire (FIQ), and Patient Global Impression of Change (PGI-C).
The percentage of participants who met all 3 of the following criteria: Reduction of \>=20% from baseline to week 8 in both PVAS \& FIQ total score and PGI-C response of "very much better" or "much better". Analysis was based on LOCF (Last Observation Carried Forward) data. The PVAS ranges from 0 (no pain) to 100 (worst imaginable pain). The FIQ ranges from 0 (best function) to 100 (worst function). PGI-C is a 7 point likert scale measuring change in the participant's fibromyalgia symptoms that ranges from "very much worse" to "very much better"
Time frame: Baseline to week 8
| Milestone | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g |
|---|---|---|---|
| Started | 66 | 62 | 67 |
| Treated | 65 | 60 | 67 |
| Completed | 54 | 51 | 46 |
| Not completed | 12 | 11 | 21 |
| Withdrew: Adverse event | 3 | 6 | 14 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Non - compliance | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Screen failure | 1 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 |
| Withdrew: Non compliance | 0 | 0 | 1 |
| Withdrew: Chronic migraine headaches (med history) | 1 | 0 | 0 |
| Withdrew: Patient wanted to go back on med | 1 | 0 | 0 |
The percentage of participants who met all 3 of the following criteria: Reduction of \>=20% from baseline to week 8 in both PVAS \& FIQ total score and PGI-C response of "very much better" or "much better". Analysis was based on LOCF (Last Observation Carried Forward) data. The PVAS ranges from 0 (no pain) to 100 (worst imaginable pain). The FIQ ranges from 0 (best function) to 100 (worst function). PGI-C is a 7 point likert scale measuring change in the participant's fibromyalgia symptoms that ranges from "very much worse" to "very much better"
| Percentage of Participants | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g |
|---|---|---|---|
| Responders | 12.9 | 29.8 | 28.1 |
| Non - Responders | 87.1 | 70.2 | 71.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/65 (0%) | 39/65 (60%) |
| Xyrem (Sodium Oxybate) 4.5g | — | 1/60 (1.7%) | 41/60 (68.3%) |
| Xyrem (Sodium Oxybate) 6.0g | — | 1/67 (1.5%) | 52/67 (77.6%) |
| Event | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g |
|---|---|---|---|
| Respiratory Tract InfectionInfections and infestations | 0/65 | 1/60 | 0/67 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/65 | 1/60 | 0/67 |
| TachycardiaCardiac disorders | 0/65 | 0/60 | 1/67 |
| HypertensionVascular disorders | 0/65 | 0/60 | 1/67 |
| Bipolar DisorderPsychiatric disorders | 0/65 | 0/60 | 1/67 |
| Event | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g |
|---|---|---|---|
| NauseaGastrointestinal disorders | 6/65 | 10/60 | 19/67 |
| DizzinessNervous system disorders | 2/65 | 5/60 | 12/67 |
| HeadacheNervous system disorders | 4/65 | 8/60 | 11/67 |
| NasopharyngitisInfections and infestations | 3/65 | 2/60 | 9/67 |
| SinusitisInfections and infestations | 2/65 | 3/60 | 6/67 |
| VomitingGastrointestinal disorders | 0/65 | 5/60 | 4/67 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/65 | 5/60 | 1/67 |
| DiarrhoeaGastrointestinal disorders | 4/65 | 4/60 | 0/67 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/65 | 4/60 | 0/67 |
| ParaesthesiaNervous system disorders | 1/65 | 4/60 | 1/67 |
| Age Continuous(years) | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g | Total |
|---|---|---|---|---|
| Mean | 47.2 ± 10.69 | 47.2 ± 11.89 | 45.1 ± 11.51 | 46.5 ± 11.35 |
| Age, Customized(participants) | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g | Total |
|---|---|---|---|---|
| 18 - 39 Years | 16 | 14 | 23 | 53 |
| 40 - 49 Years | 24 | 19 | 17 | 60 |
| 50 - 64 Years | 22 | 26 | 25 | 73 |
| >=65 years | 4 | 3 | 2 | 9 |
| Sex: Female, Male(Participants) | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g | Total |
|---|---|---|---|---|
| Female | 62 | 58 | 64 | 184 |
| Male | 4 | 4 | 3 | 11 |
| Race/Ethnicity, Customized(Participants) | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g | Total |
|---|---|---|---|---|
| Caucasian | 59 | 56 | 65 | 180 |
| African American | 4 | 6 | 1 | 11 |
| Asian | 0 | 0 | 1 | 1 |
| Hispanic | 2 | 0 | 0 | 2 |
| Other | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Placebo | Xyrem (Sodium Oxybate) 4.5g | Xyrem (Sodium Oxybate) 6.0g | Total |
|---|---|---|---|---|
| United States | 66 | 62 | 67 | 195 |
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jazz Pharmaceuticals